An Update on the Use of Botulinum Toxin Therapy in Parkinson’s Disease

被引：0
作者：
Reversa Mills
Laxman Bahroo
Fernando Pagan
机构：
[1] Georgetown University Hospital,Movement Disorders Division, Department of Neurology
来源：
Current Neurology and Neuroscience Reports | 2015年 / 15卷
关键词：
Parkinson’s disease; Non-motor symptoms; Botulinum toxin; Cervical dystonia; Foot dystonia; Focal hand dystonia; Laryngeal dystonia; Oromandibular dystonia; Blepharospasm; Lid apraxia; Camptocormia; Tremor; Sialorrhea; Hyperhidrosis; Dysphagia; Constipation; Overactive bladder;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Botulinum toxin (BoNT) has gained widespread use in a variety of neurological conditions. Parkinson’s disease is a complex neurodegenerative disorder manifested by motor and non-motor symptoms that can cause significant disability. BoNT has been used to effectively treat a variety of symptoms related to Parkinson’s disease. This review will examine the current therapeutic indications of BoNT use in the following disorders related to Parkinson’s disease: cervical dystonia, blepharospasm and lid apraxia, focal hand dystonia, foot dystonia, laryngeal dystonia, oromandibular dystonia, camptocormia, hand and jaw tremor, sialorrhea, hyperhidrosis, dysphagia, constipation, and overactive bladder.
引用
收藏
相关论文
共 267 条
[1]  
Kowal SL(2013)The current and projected economic burden of Parkinson’s disease in the United States: economic burden of PD in the US Mov Disord 28 311-318
[2]  
Dall TM(2009)The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease Mov Disord 24 1641-1649
[3]  
Chakrabarti R(2011)Parkinson’s disease: the non-motor issues Parkinsonism Relat Disord 17 717-723
[4]  
Storm MV(2006)Treatment of advanced Parkinson’s disease Expert Rev Neurother 6 1181-1197
[5]  
Jain A(2009)Disease-oriented approach to botulinum toxin use Toxicon 54 614-623
[6]  
Barone P(2007)Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson’s disease Expert Rev Neurother 7 637-647
[7]  
Antonini A(2013)Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders Toxicon 67 94-114
[8]  
Colosimo C(2008)Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology 70 1699-1706
[9]  
Chaudhuri KR(2013)Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders Toxicon Off J Int Soc Toxinology 67 141-152
[10]  
Odin P(2008)Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology 70 1707-1714
12345678910